UK markets closed
  • FTSE 100

    7,051.48
    -26.87 (-0.38%)
     
  • FTSE 250

    23,608.79
    -221.39 (-0.93%)
     
  • AIM

    1,266.98
    -5.42 (-0.43%)
     
  • GBP/EUR

    1.1668
    -0.0015 (-0.13%)
     
  • GBP/USD

    1.3674
    -0.0047 (-0.34%)
     
  • BTC-GBP

    30,643.17
    -2,292.00 (-6.96%)
     
  • CMC Crypto 200

    1,042.24
    -60.82 (-5.51%)
     
  • S&P 500

    4,449.39
    +0.41 (+0.01%)
     
  • DOW

    34,768.81
    +3.99 (+0.01%)
     
  • CRUDE OIL

    74.04
    +0.74 (+1.01%)
     
  • GOLD FUTURES

    1,751.10
    +1.30 (+0.07%)
     
  • NIKKEI 225

    30,248.81
    +609.41 (+2.06%)
     
  • HANG SENG

    24,192.16
    -318.82 (-1.30%)
     
  • DAX

    15,531.75
    -112.22 (-0.72%)
     
  • CAC 40

    6,638.46
    -63.52 (-0.95%)
     

Freeline to Participate in Upcoming Investor Conferences in September 2021

  • Oops!
    Something went wrong.
    Please try again later.
·1-min read
In this article:
  • Oops!
    Something went wrong.
    Please try again later.

LONDON, Sept. 07, 2021 (GLOBE NEWSWIRE) -- Freeline Therapeutics Holdings plc (Nasdaq: FRLN) (the “Company” or “Freeline”), a clinical-stage biotechnology company developing transformative AAV-mediated gene therapies for patients suffering from inherited systemic debilitating diseases, today announced that Chief Executive Officer Michael Parini is scheduled to present at the following virtual investor conferences:

  • H.C. Wainwright 23rd Annual Global Investment Conference on September 13, 2021, Fireside Chat that will be made available on-demand starting at 7:00 a.m. ET.

  • Morgan Stanley 19th Annual Global Healthcare Conference on September 15, 2021, Fireside Chat at 8:45 a.m. ET.

Webcasts for both presentations will be available on the Investors section of the Freeline website for 90 days. Senior management will also participate in virtual one-on-one meetings with investors at both conferences.

About Freeline Therapeutics

Freeline is a clinical-stage biotechnology company developing transformative adeno-associated virus (“AAV”) vector-mediated systemic gene therapies. The Company is dedicated to improving patient lives through innovative, one-time treatments that provide functional cures for inherited systemic debilitating diseases. Freeline uses its proprietary, rationally-designed AAV vector, along with novel promoters and transgenes, to deliver a functional copy of a therapeutic gene into human liver cells, thereby expressing a persistent functional level of the missing protein into the patient’s bloodstream. The Company’s integrated gene therapy platform includes in-house capabilities in research, clinical development, manufacturing and commercialization. The Company has clinical programs in Hemophilia B and Fabry disease, as well as preclinical programs in Gaucher disease Type 1 and Hemophilia A. Freeline is headquartered in the UK and has operations in Germany and the US.

Contact

David S. Arrington
Vice President Investor Relations & Corporate Communications
Freeline Therapeutics
david.arrington@freeline.life
+1 (646) 668 6947


Our goal is to create a safe and engaging place for users to connect over interests and passions. In order to improve our community experience, we are temporarily suspending article commenting